536
Views
8
CrossRef citations to date
0
Altmetric
Review Article

Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop

, , , , , , , , , , , , , & show all
Pages 1151-1158 | Received 27 Aug 2012, Accepted 27 Oct 2012, Published online: 10 Dec 2012
 

Abstract

Following the 53rd annual meeting of the American Society of Hematology (ASH) in San Diego in December 2011, a group of clinical and laboratory investigators convened for the 6th Post-ASH International Workshop on Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN). The Workshop took place on 13–14 December at the Estancia, La Jolla, California, USA. This report summarizes the most recent advances in the biology and therapy of CML that were presented at the ASH meeting and discussed at the Workshop. Preclinical studies focused on the CML stem cell and its niche, and on early results of deep sequencing of CML genomes. Clinical advances include updates on second- and third-generation tyrosine kinase inhibitors (TKIs), molecular monitoring, TKI discontinuation studies and new therapeutic agents. A report summarizing the pertinent advances in MPN has been published separately.

Acknowledgements

The participants of the 6th Post-ASH Workshop on CML and MPN were: Chairs: A. Tefferi and T. Mughal; Guest speaker: D. Scadden; Faculty: O. Abdel-Wahab, T. Barbui, G. Barosi, O. Bernard, K. Bhalla, M. Cazzola, J. Crispino, G. Finazzi, C. Gambacorti-Passerini, H. Gissingler, J. Goldman, J. Gotlib, P. Guglielmelli, V. Gupta, R. Hehlmann, O. Hantschel, R. Hoffman, C. Jamieson, J. Kiladjian, R. Kralovics, G. Martinelli, M. Mauro, P. Noel, T. Odenike, H. Pahl, A. Pardanani, D. Perrotti, J. Radich, F. Ravandi, G. Saglio, T. Skorski, S. Soverini, J. Thiele, R. A. Van Etten, A. Vannucchi.

This Workshop and related activities were made possible by an unrestricted educational grant from Incyte Corporation, and by the Alpine Oncology Foundation who received unrestricted support from Sanofi Oncology, Bristol-Myers Squibb and YM Bioscience. Special thanks go to Alpa Parmar and Susannne Blassingale for their help, and to the Postgraduate Institute for Medicine for CME accreditation. Preparation of this manuscript was supported in part by NIH grants CA0905756 to R.A.V. and CA134458 and CA123014 to T.S.

Potential conflict of interest:

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.